Role of P2X7 receptor in colon cancer progression

doi:10.3760/cma.j.cn371439-20200903-00050

Abstract

Abstract:

P2X7 receptor is an ion channel receptor with adenosine triphosphate (ATP) as its ligand, which is widely expressed in various immune cells and tissues. Activated P2X7 receptor is involved in a variety of physiological and pathological processes. P2X7 receptor is abnormally expressed in colon cancer, and plays a duel role of cancer-promoting and cancer-suppressing in colon cancer progression. When P2X7 receptor is activated by extracellular ATP, it can effectively inhibit proliferation and induce apoptosis of colon cancer cells through various mechanisms. In addition, P2X7 receptor can also promote the growth, invasion and metastasis of colon cancer. Understanding the activation of P2X7 receptor and its effect mechanism is of great significance for the treatment of colon cancer.

Key words: Receptors, purinergic P2X7, Colonic neoplasms, Adenosine triphosphate

Li Qianqian, Zhu Xiaodi, Zhao Ronglan, Peng Xiaoxiang. Role of P2X7 receptor in colon cancer progression[J]. Journal of International Oncology, 2021, 48(4): 250-253.

References 28

[1]	Lv Y, Yang X, Wang L. Effect of lncRNA THOR on proliferation and migration of colon cancer cells[J]. Oncol Lett, 2019, 18(3):2518-2522. DOI: 10.3892/ol.2019.10585.
[2]	Di Virgilio F, Pelegrín P. Editorial overview: purinergic P2X receptors in innate immunity and inflammation[J]. Curr Opin Pharmacol, 2019, 47:141-144. DOI: 10.1016/j.coph.2019.05.003. doi: 10.1016/j.coph.2019.05.003
[3]	Zhang WJ, Hu CG, Zhu ZM, et al. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties[J]. Biomed Pharmacother, 2020, 125:109844. DOI: 10.1016/j.biopha.2020.109844. doi: 10.1016/j.biopha.2020.109844
[4]	Roger S, Jelassi B, Couillin I, et al. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives[J]. Biochim Biophys Acta, 2015, 1848(10 Pt B):2584-2602. DOI: 10.1016/j.bbamem.2014.10.029. doi: 10.1016/j.bbamem.2014.10.029
[5]	Cao F, Hu LQ, Yao SR, et al. P2X7 receptor: a potential therapeutic target for autoimmune diseases[J]. Autoimmun Rev, 2019, 18(8):767-777. DOI: 10.1016/j.autrev.2019.06.009. doi: 10.1016/j.autrev.2019.06.009
[6]	Ribeiro DE, Roncalho AL, Glaser T, et al. P2X7 receptor signaling in stress and depression[J]. Int J Mol Sci, 2019, 20(11): 2778. DOI: 10.3390/ijms20112778. doi: 10.3390/ijms20112778
[7]	Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth[J]. Oncogene, 2017, 36(3):293-303. DOI: 10.1038/onc.2016.206. doi: 10.1038/onc.2016.206 pmid: 27321181
[8]	Furini F, Giuliani AL, Parlati ME, et al. P2X7 receptor expression in patients with serositis related to systemic lupus erythematosus[J]. Front Pharmacol, 2019, 10:435. DOI: 10.3389/fphar.2019.00435. doi: 10.3389/fphar.2019.00435
[9]	Amoroso F, Salaro E, Falzoni S, et al. P2X7 targeting inhibits growth of human mesothelioma[J]. Oncotarget, 2016, 7(31):49664-49676. DOI: 10.18632/oncotarget.10430. doi: 10.18632/oncotarget.v7i31
[10]	Choi JH, Ji YG, Ko JJ, et al. Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1/2 and JNK[J]. Pancreas, 2018, 47(5):643-651. DOI: 10.1097/MPA.0000000000001055. doi: 10.1097/MPA.0000000000001055 pmid: 29683976
[11]	Xia J, Yu X, Tang L, et al. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway[J]. Oncol Rep, 2015, 34(1):103-110. DOI: 10.3892/or.2015.3979. doi: 10.3892/or.2015.3979
[12]	Hofman P, Cherfils-Vicini J, Bazin M, et al. Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer[J]. Cancer Res, 2015, 75(5):835-845. DOI: 10.1158/0008-5472.CAN-14-1778. doi: 10.1158/0008-5472.CAN-14-1778
[13]	陆嫄, 顾沐恩, 丁邦友, 等. 艾灸对结肠炎相关性结肠癌大鼠P2X7受体、Wnt/β-catenin信号通路影响的研究[J]. 上海针灸杂志, 2020, 39(6):758-765. DOI: 10.13460/j.issn.1005-0957.2020.13.1042.
[14]	Wang J, Cheng M, Law IKM, et al. Cathelicidin suppresses colon cancer metastasis via a P2RX7-dependent mechanism[J]. Mol Ther Oncolytics, 2019, 12:195-203. DOI: 10.1016/j.omto.2019.01.004. doi: 10.1016/j.omto.2019.01.004
[15]	Adinolfi E, Capece M, Franceschini A, et al. Accelerated tumor progression in mice lacking the ATP receptor P2X7[J]. Cancer Res, 2015, 75(4):635-644. DOI: 10.1158/0008-5472.CAN-14-1259. doi: 10.1158/0008-5472.CAN-14-1259
[16]	Di Virgilio F, Sarti AC, Falzoni S, et al. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment[J]. Nat Rev Cancer, 2018, 18(10):601-618. DOI: 10.1038/s41568-018-0037-0. doi: 10.1038/s41568-018-0037-0
[17]	He Y, Taylor N, Fourgeaud L, et al. The role of microglial P2X7: modulation of cell death and cytokine release[J]. J Neuroinflammation, 2017, 14(1):135. DOI: 10.1186/s12974-017-0904-8. doi: 10.1186/s12974-017-0904-8
[18]	Bian S, Sun X, Bai A, et al. P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death[J]. PLoS One, 2013, 8(4): e60184. DOI: 10.1186/s12974-017-0904-8. doi: 10.1371/journal.pone.0060184
[19]	Coutinho-Silva R, Stahl L, Cheung KK, et al. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 288(5): G1024-G1035. DOI: 10.1152/ajpgi.00211.2004. doi: 10.1152/ajpgi.00211.2004
[20]	Souza CO, Santoro GF, Figliuolo VR, et al. Extracellular ATP induces cell death in human intestinal epithelial cells[J]. Biochim Biophys Acta, 2012, 1820(12):1867-1878. DOI: 10.1016/j.bbagen.2012.08.013.
[21]	de Andrade Mello P, Bian S, Savio LEB, et al. Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death[J]. Oncotarget, 2017, 8(40):67254-67268. DOI: 10.18632/oncotarget.18595. doi: 10.18632/oncotarget.v8i40
[22]	Adinolfi E, Raffaghello L, Giuliani AL, et al. Expression of P2X7 receptor increases in vivo tumor growth[J]. Cancer Res, 2012, 72(12):2957-2969. DOI: 10.1158/0008-5472.CAN-11-1947. doi: 10.1158/0008-5472.CAN-11-1947
[23]	Janakiram NB, Mohammed A, Bryant T, et al. Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein[J]. Mol Carcinog, 2015, 54(10):986-998. DOI: 10.1002/mc.22168. doi: 10.1002/mc.22168
[24]	方伟岗, 田新霞. 肿瘤微环境中一种新型促侵袭因子的发现——细胞外ATP功能及机制的研究进展[J]. 北京大学学报(医学版), 2017, 49(2):188-195. DOI: 10.3969/j.issn.1671-167X.2017.02.002.
[25]	Zhang Y, Ding J, Wang L. The role of P2X7 receptor in prognosis and metastasis of colorectal cancer[J]. Adv Med Sci, 2019, 64(2):388-394. DOI: 10.1016/j.advms.2019.05.002. doi: 10.1016/j.advms.2019.05.002
[26]	Qian F, Xiao J, Hu B, et al. High expression of P2X7R is an in-dependent postoperative indicator of poor prognosis in colorectal cancer[J]. Hum Pathol, 2017, 64:61-68. DOI: 10.1016/j.humpath.2017.03.019. doi: 10.1016/j.humpath.2017.03.019
[27]	Kaltschmidt B, Greiner JFW, Kadhim HM, et al. Subunit-specific role of NF-κB in cancer[J]. Biomedicines, 2018, 6(2):44. DOI: 10.3390/biomedicines6020044. doi: 10.3390/biomedicines6020044
[28]	Xia Y, Shen S, Verma IM. NF-κB, an active player in human can-cers[J]. Cancer Immunol Res, 2014, 2(9):823-830. DOI: 10.1158/2326-6066.CIR-14-0112. doi: 10.1158/2326-6066.CIR-14-0112